Neuro-Oncology is the Society for Neuro-Oncology's journal, publishing glioma, brain metastasis and paediatric brain tumour research, response criteria and the CBTRUS statistical reports.
Publishes the annual CBTRUS statistical report on US brain tumours, the RANO response-assessment criteria, molecular classification work that feeds the WHO CNS tumour classification, and phase 2 trials in glioma. Hybrid access via Oxford University Press; the SNO annual meeting abstracts appear as a supplement.
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Response-adapted, reduced-dose whole-ventricular radiotherapy after chemotherapy is now a standard for localised germinoma in North American protocols.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Observation for small asymptomatic tumours, adjuvant radiotherapy for incompletely resected grade 2 and all grade 3 tumours, and the referral of refractory cases to trials on this site's meningioma page follow this guideline.
Every brain tumour page on this site uses these names and grades; a tumour called glioblastoma before 2021 may now be an IDH-mutant astrocytoma with a different outlook and treatment.
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited papers Europe PMC returns for Andrew B. Lassman at Herbert Irving Comprehensive Cancer Center, Columbia University, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Carboplatin in Glioma & glioblastoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Chemotherapy followed by whole-ventricular irradiation with a tumour boost, rather than craniospinal irradiation, is the standard for localised germinoma, sparing children the neurocognitive and endocrine cost of wider fields.
One of the most cited trial reports Europe PMC returns for Carboplatin in Glioma & glioblastoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival.
Geneticist known for work on the genetic drivers of childhood brain cancer who became Director and CEO of QIMR Berghofer, a leading Australian medical research institute, in 2026.
Ian Cree edits the WHO 'Blue Books', the classification every pathologist uses to name a cancer.
Neuro-oncologist who created the RANO response criteria used in every brain tumour trial and leads glioblastoma drug development.
One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Response-adapted, reduced-dose whole-ventricular radiotherapy after chemotherapy is now a standard for localised germinoma in North American protocols.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Observation for small asymptomatic tumours, adjuvant radiotherapy for incompletely resected grade 2 and all grade 3 tumours, and the referral of refractory cases to trials on this site's meningioma page follow this guideline.
Every brain tumour page on this site uses these names and grades; a tumour called glioblastoma before 2021 may now be an IDH-mutant astrocytoma with a different outlook and treatment.
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One of the most cited papers Europe PMC returns for Andrew B. Lassman at Herbert Irving Comprehensive Cancer Center, Columbia University, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma, Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma, Glioma & glioblastoma.
Shares ACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma, SIOP CNS GCT 96: outcomes for children and adults with intracranial germinoma treated with radiotherapy alone or chemotherapy plus reduced radiotherapy, The 2021 WHO classification of tumours of the central nervous system: a summary.
Shares Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial, Glioma & glioblastoma.
Shares Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter, Glioma & glioblastoma.
Shares Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, Glioma & glioblastoma.
Shares EANO guideline on the diagnosis and management of meningiomas (2021), The 2021 WHO classification of tumours of the central nervous system: a summary, Glioma & glioblastoma.
Shares Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group, Glioma & glioblastoma.
Shares Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors, Journal of neuro-oncology.